Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
This is the biggest and best news–maybe ever–for the safe and effective treatment of chronic melasma and hyperpigmentation. The difference is bio-available azelaic acid, a well-known and proven ingredient now with a patent-pending, novel delivery system. Combined with NOON’s patented DermShield™ technology, Azelaic-Br creates and maintains brighter, even-toned skin without irritation. It’s not just a hope or a hype. It’s a promise. And it is clinically proven.
Azelaic-Br 13 has a 13% concentration of azelaic acid, Azelaic-Br 20 has a 20% concentration.
Effectively inhibits production of excess melanin.
Offers preventative and long term treatment for dark and hyperpigmented skin.
Two potent acids, paired with DermShield, work hard to deliver effective results, without irritation.
Non-photosensitive.
Targets hyperactive melanocytes without affecting normal, healthy cells.
Non-toxic and safe for all skin types.
Has significant keratolytic properties to renew and refresh the skin surface.
This is the biggest and best news–maybe ever–for the safe and effective treatment of chronic melasma and hyperpigmentation. The difference is bio-available azelaic acid, a well-known and proven ingredient now with a patent-pending, novel delivery system. Combined with NOON’s patented DermShield™ technology, Azelaic-Br creates and maintains brighter, even-toned skin without irritation. It’s not just a hope or a hype. It’s a promise. And it is clinically proven.
Azelaic-Br 13 has a 13% concentration of azelaic acid, Azelaic-Br 20 has a 20% concentration.
Effectively inhibits production of excess melanin.
Offers preventative and long term treatment for dark and hyperpigmented skin.
Two potent acids, paired with DermShield, work hard to deliver effective results, without irritation.
Non-photosensitive.
Targets hyperactive melanocytes without affecting normal, healthy cells.
Non-toxic and safe for all skin types.
Has significant keratolytic properties to renew and refresh the skin surface.
